About
Technology
Issues
FAQ
Links
Official Page
Phase I/
II
study of vemurafenib in patients with unresectable or recurrent melanoma with
BRAF
V
600
mutations
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.